title: Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.
abstract: As no specific genetic lesions have yet been identified, the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms is based on a simultaneous evaluation of the clinical, morphological and molecular features defined by the updated WHO classification, which allow most cases of full-blown disease to be classified. Nevertheless, about 10-15% of the patients have unclassifiable myeloproliferative neoplasms, most of whom are in the prodromal (early) phase of disease and identified by the presence of the JAK2 mutation, but lack the complete phenotype required by the WHO classification. The detection of these prodromal phases is extremely important in order to prevent dramatic thrombo-hemorrhagic complications and improve prognosis.
authors: Department of Pathophysiology and Transplantation, Division of Pathology, Hematopathology Service, University of Milan Medical School, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, Via Francesco Sforza 35, 20122 Milano, Italy.
authors: Umberto
authors: U
authors: Gianelli
authors: Alessandra
authors: A
authors: Iurlo
authors: Daniele
authors: D
authors: Cattaneo
authors: Giorgio
authors: G
authors: Lambertenghi-Deliliers
mesh_terms: D001853:Bone Marrow / Q000473:pathology; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics / Q000378:metabolism; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008533:Megakaryocytes / Q000473:pathology; D009154:Mutation; D055728:Primary Myelofibrosis / Q000175:diagnosis / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D013922:Thrombocytosis / Q000175:diagnosis
chemical_list: D047428:Protein Kinase Inhibitors; C507924:JAK2 protein, human; D053614:Janus Kinase 2